Tenaya Therapeutics, Inc. (TNYA)
0.389
0.00 (0.00%)
USD |
NASDAQ |
Oct 23, 16:00
0.3897
0.00 (0.00%)
After-Hours: 20:00
Tenaya Therapeutics Enterprise Value : 13.09M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 13.09M |
| October 22, 2026 | 12.87M |
| October 21, 2026 | 13.36M |
| October 20, 2026 | 17.80M |
| October 19, 2026 | 10.53M |
| October 16, 2026 | 11.23M |
| October 15, 2026 | 17.44M |
| October 14, 2026 | 13.43M |
| October 13, 2026 | 42.69M |
| October 12, 2026 | 52.67M |
| October 09, 2026 | 55.98M |
| October 08, 2026 | 47.89M |
| October 07, 2026 | 45.47M |
| October 06, 2026 | 48.41M |
| October 05, 2026 | 52.35M |
| October 02, 2026 | 52.35M |
| October 01, 2026 | 52.71M |
| September 30, 2026 | 61.21M |
| September 29, 2026 | 58.85M |
| September 28, 2026 | 58.11M |
| September 25, 2026 | 62.55M |
| September 24, 2026 | 64.89M |
| September 23, 2026 | 74.15M |
| September 22, 2026 | 78.83M |
| September 21, 2026 | 76.95M |
| Date | Value |
|---|---|
| September 18, 2026 | 78.18M |
| September 17, 2026 | 76.59M |
| September 16, 2026 | 73.34M |
| September 15, 2026 | 76.21M |
| September 14, 2026 | 81.23M |
| September 11, 2026 | 69.37M |
| September 10, 2026 | 71.34M |
| September 09, 2026 | 74.08M |
| September 08, 2026 | 74.62M |
| September 04, 2026 | 79.06M |
| September 03, 2026 | 81.77M |
| September 02, 2026 | 82.67M |
| September 01, 2026 | 79.55M |
| August 31, 2026 | 80.09M |
| August 28, 2026 | 80.61M |
| August 27, 2026 | 81.75M |
| August 26, 2026 | 81.97M |
| August 25, 2026 | 83.14M |
| August 24, 2026 | 77.15M |
| August 21, 2026 | 82.22M |
| August 20, 2026 | 80.69M |
| August 19, 2026 | 85.72M |
| August 18, 2026 | 82.49M |
| August 17, 2026 | 82.85M |
| August 14, 2026 | 89.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.39M |
| Revenue (Quarterly) | 1.11M |
| Total Expenses (Quarterly) | 44.50M |
| EPS Diluted (Quarterly) | -0.1994 |
| Gross Profit Margin (Quarterly) | -52.97% |
| Profit Margin (Quarterly) | -3.91K% |
| Earnings Yield | -135.6% |
| Normalized Earnings Yield | -116.48 |